You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股逆市造好 康方、歌禮製藥及百濟神州漲近10%-14%
英倫銀行行長貝利警告全球經濟前景顯著惡化,美國債券孳息曲線再次呈倒掛被視為經濟衰退預警,商品價格下挫,尤其是遭花旗唱淡油價急跌逾8%-9%,歐洲主要股市昨晚全面急挫2.1%-3%;道指由最多急挫742點或2.4%,收窄至僅跌129點或0.4%。亞太主要股市早段全面受壓,尤其是日經及台股吐逾1%。恆指繼昨天反彈受制22,200後,今早曾低見21,681,現報21,700,跌152點或0.7%,總成交額433億元。 然而,野村日前認為內地醫藥行業估值具吸引力。醫藥股今天逆市造好,日前獲野村給予「買入」的評級百濟神州(06160.HK)繼昨天稍作整固後,今早股價高見122.8元創近三個月高,現報122.1元,急漲近14%。 歌禮製藥-B(01672.HK)高見4.36元,現報4.3元,回升11%;康方生物-B(09926.HK)高見28.55元,創近半年高,現報28.2元,回升9.9%。開拓藥業-B(09939.HK)高見19.1元,現報18.72元,回升4%。 藍籌藥明生物(02269.HK)、藥明康德(02359.HK)、康希諾生物(06185.HK)、君實生物(01877.HK)、金斯瑞生物(01548.HK)、信達生物(01801.HK)及騰盛博藥(02137.HK)升逾2%-4%,後兩者最強分別高見41元及8.92元。 野村日前認為,內地醫藥公司基本面並非似股價表現一樣弱,去年度大多數中國醫療保健公司業績都令人滿意,製藥行業也在快速擴張,研發及新藥申請增加,認為行業估值具吸引力。此外,今年國家醫保目錄談判將於下半年舉行,預期降價對製藥企業影響將略有緩解,預期對於生物技術公司而言,海外市場的臨床及監管進展將是最大的催化劑。該行看好製藥及合同研究機構(CRO),首選仍為中生製藥(01177.HK),CRO方面則看好藥明康德,生物技術領域看好百濟神州,全部給予「買入」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account